Division of GlaxoSmithKline PLC
Latest From ViiV Healthcare
AlloVir/Baylor, Soligenix/Hawaii and CEL-SCI/Georgia ink coronavirus collaborations, but deal-making continues in other areas as well, including Asklepios/UNC teaming on a gene therapy for Angelman syndrome and DeMelle licensing a targeted pancreatic cancer drug from Moffitt, among others.
EU marketing applications from Vertex and Roche have reverted to standard review timelines at the European Medicines Agency. The outcomes of three fast-track requests that companies have made for their planned filings are still unknown.
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.
Hot on the heels of winning EU fast-track review status for belantamab mafodotin, GlaxoSmithKline has asked the European Medicines Agency to grant accelerated assessment to another of its planned marketing applications.
- Therapeutic Areas
- Infectious & Viral Diseases
- GSK Pfizer HIV
- Western Europe
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Jerome Andries, CFO
John Pottage, MD, CSO & CMO
Gregory Reinaud, Head, Global Commercial Strategy
- Contact Info
Phone: (44) (0)20 8380 6200
980 Great West Rd.
Brentford, TW8 9GS
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.